Mateon Therapeutics, Inc. (OTCMKTS:MATN – Get Free Report)’s share price passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.06 and traded as high as $0.11. Mateon Therapeutics shares last traded at $0.10, with a volume of 425,894 shares traded.
Mateon Therapeutics Price Performance
The firm’s 50 day simple moving average is $0.07 and its two-hundred day simple moving average is $0.06.
About Mateon Therapeutics
Mateon Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-beta, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus.
Featured Articles
- Five stocks we like better than Mateon Therapeutics
- Ride Out The Recession With These Dividend Kings
- Warner Bros. Bidding War Potential: How High Could WBD Shares Go?
- 3 Warren Buffett Stocks to Buy Now
- Analysts Eye 30% Upside in Netflix After Q3 Earnings Crash
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- O’Reilly Automotive’s Stock Price Uptrend Will Continue in 2026
Receive News & Ratings for Mateon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mateon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
